Institution identification

PURI

https://redirect.ema.europa.eu/resource/3068

Institution ID

3068

Institution full name and acronym

Real World Evidence Solutions, IMS Health

Institution countries

France

Type of institution

Other

Institution website

ENCePP partner

Yes
Institution description
Supported by the most comprehensive,advanced and credential tools and databases available in the world,we carry out two major kinds of research:1) Conventional ad-hoc epidemiological,pharmacoepidemiological,health economics and safety studies using both observational and interventional methodologies.2) Innovative studies on Real World Data (RWD): these are databases of de-identified electronic health records gathered over a long period of time from a panel of physicians,pharmacists,hospitals,nurses,etc. This unique source of data helps us designing and conducting a variety of studies directly through the databases. These include safety,and drug utilisation studies,but also studies on diagnoses,acts,patient adherence,therapeutic reasoning,quality of life,and cost of care.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A Drug Utilisation Study of Domperidone in Europe Using Databases
Assessment of the effectiveness of risk minimisation measures set up for new safety information for Efient® (Prasugrel): a multinational survey among physicians to evaluate their knowledge and consideration of the new safety warning for Prasugrel in four European countries (H7T-MC-B021)
Assessment of the safety of LABAs in asthma in routine care by combining healthcare databases and direct patient follow-up (ASTRO-LAB)
Drug utilisation study (DUS) on flupirtine-containing medicinal products
Drug utilisation study (DUS) on flupirtine-containing products Retrospective drug utilisation study using patient-level databases to characterise prescribing practices of flupirtine-containing drugs during routine clinical use and assess the main reasons for prescription by representative groups of prescribers
Drug Utilisation Study for Olodaterol
Drug Utilisation Study of conjugated oestrogens/bazedoxifene (CE/BZA) in the European Union (EU)
Drug utilisation study, in five European countries, using cross sectional analysis, to assess the extent of prescriptions of trimetazidine for its withdrawn ophthalmological and ENT indications among general practitioners, ophthalmologists and ENT specialists
Drug Utilization Study for azilsartan medoxomil in Germany
Drug utilization study for Elvanse® / Tyvense® / Elvanse® Adult in Europe
Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic use in France and Italy: an electronic medical records databases study
Drug Utilization Study of ZALTRAP® (aflibercept) Using European Databases (Zaltrap Utilization Study)
European Drug Usage Survey for Amyvid (I6E-MC-AVBF)
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Thiocolchicoside containing Medicinal Products for Systemic Use in France, Greece, Italy and Portugal
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Trimetazidine in Bulgaria, Czech Republic, Estonia, France, Hungary, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, and Spain
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey and Drug Utilisation Study among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of valproate in France, Germany, Spain, Sweden and United Kingdom
Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Instanyl® in France and the Netherlands
Evaluation of the Effectiveness of Risk Minimization Measures: Trimetazidine Drug Utilization Study in European Countries using databases – analysis for France, Hungary, Romania and Spain
Monitoring of Compliance with Exenatide Prescribing Guidelines in Canada: Drug Utilisation Study of BYETTA in Canada for 2011-2014
Observational single-cohort data base study of dapagliflozin utilisation in Europe (NA)
Patient real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera® and Rebif®: A retrospective study (PROTRACT)
Post-Authorisation Safety Study (PASS) for Flupirtine – Effect of Risk Minimisation Measures in Germany
Prevalence and Incidence of Problematic Prescription Opioid Use and Abuse in the United Kingdom and Germany (OXY9504)
Severe hypersensitivity reactions associated with high dose iv iron containing medicinal products
Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report
Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report (B4Z-MC-B026)
Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)